4.5 Review

Sleep Apnea, Aldosterone, and Resistant Hypertension

Journal

PROGRESS IN CARDIOVASCULAR DISEASES
Volume 51, Issue 5, Pages 371-380

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.pcad.2008.02.004

Keywords

-

Funding

  1. Astra-Zeneca
  2. CV Therapeutics
  3. Novartis
  4. Abbott Laboratories
  5. Aventis
  6. Biovail
  7. Boehringer Ingelheim
  8. Bristol Myers-Squibb
  9. Forest Laboratories
  10. GlaxoSmithKline
  11. Merck Co
  12. Pfizer
  13. Sankyo Pharma
  14. Sanofi-Synthelabo

Ask authors/readers for more resources

Obstructive sleep apnea, aldosterone excess, and resistant hypertension are common comorbidities in obese patients. The mechanisms that link these conditions are not fully elucidated, but sympathetic nervous system activation, sodium retention, renin-angiotensin-aldosterone system stimulation, endothelial dysfunction, and increased production of reactive oxidative species may be contributing factors. Patients diagnosed with this triad should be treated with low-salt diet, weight-loss counseling, and continuous positive airway pressure, as well as aggressive antihypertensive therapy, usually with multiple agents, including a mineralocorticoid receptor antagonist. Patients with aldosterone-producing adenoma may require adrenalectomy. (C) 2009 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available